Articles and Videos
IntegraSyn™ – a flexible, high yield and cost-effective cannabinoid manufacturing system
InMed’s scientific team has developed IntegraSyn™ - a flexible, high yield and cost-effective manufacturing system to produce pharmaceutical-grade, bio-identical cannabinoids. InMed recently announced that IntegraSyn™...
Source: BTV
Cannabinol – charting new paths for glaucoma treatment
InMed Pharmaceuticals, a clinical stage pharmaceutical company based in Vancouver, Canada, is developing rare cannabinoid–based therapeutic drug candidates for patients who may benefit from the...
Ensuring Cannabis safety – shifting from anecdotal to scientific evidence
Cannabis has been used for centuries, with evidence suggesting its medicinal use as early as 400 B.C. Interest in Cannabis’ potential medical benefits has garnered...
Current research into the potential therapeutic effects of cannabinol (CBN)
How do cannabinoids interact with the human body? There has been a significant growth in interest and research into the potential therapeutic properties of cannabinoids....
InMed’s CEO Eric A. Adams presents at Edison Open House: Global Healthcare 2021
InMed Pharmaceuticals CEO, Eric A. Adams, is interviewed by Science Journalist and Broadcaster Vivienne Parry Obe at the Edison Open House: Global Healthcare Conference 2021....
Source: Edison TV
Cannabinol 101: The Science of Cannabinol (CBN)
Cannabinol, or CBN for short, is one of the more than 100 rare cannabinoids found in the Cannabis plant. CBN is found in aged Cannabis...
